New data from the World Health Organization (WHO) show that the GAVI Alliance, a groundbreaking global initiative to increase access to children’s vaccines, has brought immunisation rates to record highs in poor countries.
The WHO data, released today at the World Economic Forum’s annual meeting, project that since 2000, GAVI-funded immunisation programs in developing countries have prevented approximately 2.3 million future deaths, and that immunisations in 2006 alone prevented 600,000 future deaths.
Bill and Melinda Gates, co-chairs of the Bill & Melinda Gates Foundation, called the new data a highly encouraging sign of progress in global health. The Gates Foundation has committed a total of US$1.5 billion to support GAVI to date. GAVI has also received funding from 17 donor governments, including Germany, which recently committed €8 million (US$10.4 million).
"GAVI and its partners are leading a major turnaround in children’s health," said Melinda Gates. "When GAVI was founded, immunisation rates in poor countries were on the decline. Today, they are at an all-time high."
Since its inception in 2000, GAVI has committed US$2.6 billion to support national immunisation programs in more than 70 developing countries. According to the WHO projections released today, as a result of GAVI funding:
- 28 million more children have been protected against diphtheria, tetanus, and pertussis, helping to increase overall immunisation rates for these diseases from 63 percent in 1999 to 77 percent in 2006.
- 138 million more children have received new and under-used vaccines, such as those for hepatitis B, Hib, and yellow fever, helping to greatly increase immunisation coverage for these diseases. For example, the number of developing countries providing hepatitis B vaccine rose from 15 in 1999 to 61 in 2006.
"GAVI has demonstrated that with the right resources and leadership, it is possible to make dramatic health gains in poor countries," said Bill Gates. "We need to build on this success. No child should be denied access to lifesaving immunisations."
Despite GAVI’s progress, in 2005, an estimated 28 million children in developing countries were not immunised, and 2.5 million children died of vaccine-preventable diseases. To close this gap, WHO and UNICEF estimate that an additional US$10-15 billion will be needed for immunisation programs over the next decade. More funding will be needed to introduce vaccines that are currently in the development pipeline.
GAVI Commits US$500 Million to Strengthen Health Systems
In an effort to further increase global immunisation coverage, GAVI also announced today that it will invest US$500 million over five years to strengthen basic health systems in developing countries.
Weak health care infrastructure is often the main barrier to providing immunisations to children in developing countries, particularly in the poorest and most remote communities.
The new GAVI funding will provide flexible grants to developing countries for activities such as:
- Recruiting and training health care workers- Building and strengthening systems to distribute vaccines and drugs
"This is an exciting new direction for us," said Julian Lob-Levyt, Executive Secretary of GAVI. "Developing country leaders are telling us that in order for immunisation programs to be sustained, they need greater support for basic health infrastructure."
The first round of GAVI grants for strengthening health systems will be announced in February.
Jean-Pierre Le Calvez | EurekAlert!
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
Urbanization to convert 300,000 km2 of prime croplands
27.12.2016 | Mercator Research Institute on Global Commons and Climate Change (MCC) gGmbH
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).
Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...
10.01.2017 | Event News
09.01.2017 | Event News
05.01.2017 | Event News
18.01.2017 | Power and Electrical Engineering
18.01.2017 | Materials Sciences
18.01.2017 | Life Sciences